Physician profile
Jack M Dodson
NPI 1821069345
$2,932.63
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $215 · 2021: $418 · 2022: $1,124 · 2023: $7.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $323.88 | 2019-2022 | |
| Abbvie INC. | $304.99 | 2021-2022 | |
| Amgen INC. | $255.07 | 2019-2022 | |
| Pfizer INC. | $248.15 | 2019-2022 | |
| Novo Nordisk INC | $198.36 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.79 | 2019-2022 | |
| Astellas Pharma US INC | $165.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $155.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $144.73 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $99.77 | 2022 | |
| Glaxosmithkline, LLC. | $71.02 | 2019-2022 | |
| Abbott Laboratories | $67.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.86 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $58.07 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.85 | 2022 | |
| Allergan, INC. | $44.40 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $43.75 | 2022 | |
| Sunovion Pharmaceuticals INC. | $41.16 | 2020-2022 | |
| Amarin Pharma, INC. | $38.68 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $30.76 | 2021 | |
| Nestle Healthcare Nutrition INC. | $29.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.51 | 2019-2021 | |
| Lundbeck LLC | $16.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.85 | 2022 | |
| Radius Health, INC. | $15.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.06 | 2019 | |
| Biogen, INC. | $11.60 | 2021 | |
| Organon LLC | $9.43 | 2022 | |
| Sumitomo Pharma America, INC. | $7.37 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.